Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1

Status

Completed 5

Sponsor Class

OTHER 12INDUSTRY 5NIH 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Neoplasms 2Thyroid Cancer, Papillary 1Solid Cancers 1Lymphoma, Follicular 1Diabetes Mellitus, Type 2 1Carcinoma, Renal Cell 1Alzheimer Disease 1Adenocarcinoma, Follicular 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Rosiglitazone × Clear all
NCT01287598 2019-07-10

BAY73-4506 Probe Substrate Study

Bayer

Phase 1 Completed
41 enrolled
Tumor-Agnostic

Neoplasms

NCT00428090 2017-05-19

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

GlaxoSmithKline

Phase 3 Completed
862 enrolled 36 charts
Lymphoid

Alzheimer Disease, Lymphoma, Follicular

NCT01209143 2015-06-29

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Genentech, Inc.

Phase 1 Completed
52 enrolled 8 charts

Solid Cancers

NCT01195259 2013-10-28

Malignancy Meta Analysis for BRL49653

GlaxoSmithKline

Completed
1 enrolled

Diabetes Mellitus, Type 2, Neoplasms

NCT01100619 2013-09-19

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Exelixis

Phase 1 Completed
40 enrolled
EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Carcinoma, Renal Cell, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡